课题基金 / 基金详情

Shared Placenta/Tumor Antigens and Maternal Immunity

Shared Placenta/Tumor Antigens and Maternal Immunity
共享胎盘/肿瘤抗原和母体免疫
批准号:
9316903
负责人:
MARGARET G PETROFF
金额:
$23.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-05-18 至 2019-04-30

项目摘要

项目成果

MARGARET G PETROFF的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Pregnancy impacts the maternal immune system and breast cancer risk, but whether these effects are related is unknown. Many women are immunologically primed to fetal antigens during pregnancy due to the unique expression of paternally- inherited antigens by the fetus. However, whether this priming has any consequence on subsequent progression of diseases in women is unknown. Tumor antigens are proteins that have limited expression in normal adult tissues, but are strongly expressed in many cancers, including cancer of the breast. Because of their ability to induce immunity, there is strong scientific and medical interest in exploiting this property for development of anti-cancer vaccines. Despite their restricted expression patterns, several, which we call shared placenta/tumor antigens, are highly expressed in the placenta. Investigators have long speculated that trophoblast cells and tumor cells share similarities, but the immunologic relationship between shared placenta/tumor antigens, breast cancer, and pregnancy are completely unknown. In this proposal, we explore the hypothesis that shared tumor/placenta antigens are immunogenic during pregnancy. These experiments serve as critical proof of concept experiments, with which we can further explore the long term hypothesis that immune priming to shared placenta tumor antigens during pregnancy alter breast cancer risk in parous women. To determine whether the placenta primes the maternal immune system against shared placenta/tumor antigens, we propose the following Specific Aims: 1. Determine whether the murine maternal immune system is primed to shared tumor/placenta antigens. 2. Test women for evidence of sensitization to shared placenta/tumor antigens. To our knowledge, this is the first time that a long-term consequence of the physiologically normal maternal immune response to fetal antigens will be considered in light of a critical clinical problem: women's cancer. In the long-term, this work could profoundly impact our understanding of why parity changes risk of breast cancer, and lead to insights into novel cancer prevention and therapeutic strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Maternal Central Immune Tolerance in Reproduction
  • 批准号:
    10396646
  • 项目类别:
  • 资助金额:
    $39.64万
  • 财政年份:
    2020
  • 负责人:
    MARGARET G PETROFF
  • 依托单位:
Maternal Central Immune Tolerance in Reproduction
  • 批准号:
    10215585
  • 项目类别:
  • 资助金额:
    $39.35万
  • 财政年份:
    2020
  • 负责人:
    MARGARET G PETROFF
  • 依托单位:
Endocrine regulation of maternal immunity in pregnancy
  • 批准号:
    10116259
  • 项目类别:
  • 资助金额:
    $19.56万
  • 财政年份:
    2020
  • 负责人:
    MARGARET G PETROFF
  • 依托单位:
Endocrine regulation of maternal immunity in pregnancy
  • 批准号:
    9979498
  • 项目类别:
  • 资助金额:
    $23.48万
  • 财政年份:
    2020
  • 负责人:
    MARGARET G PETROFF
  • 依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究